Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010–2025): 15 Years of Progress (or Lack Thereof)
CNS Drugs November 28, 2025 D J Hirsch, Jace Reed, Aasim Naqvi et al. 2 citations
Eating disorders are complex psychiatric conditions with limited pharmacological treatment options. A review of clinical drug trials from 2010 to 2025 found 43 eligible phase I-IV trials for anorexia nervosa, binge eating disorder, bulimia nervosa, and rumination disorder. Among 24 distinct compounds studied, only lisdexamfetamine dimesylate received FDA approval for an eating disorder during this period. Few agents have shown positive results in late-stage trials, though solriamfetol and psilocybin show promise. There remains a significant lack of evidence-based pharmacological interventions for anorexia nervosa and little progress for bulimia nervosa, highlighting an urgent need for more rigorous clinical trials.